We can speculate that the non-response with the 2 weeks treatment is possibly due to a selection of resistant tumor cells to NRP1 inhibition or to other mechanisms of escape involving vascularization which are well-known to targeted therapies promoting other signaling pathways. The gene discussed is NRP1; the disease is neoplasm.